Cargando…
Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies
Soft tissue sarcomas (STS) are heterogeneous rare malignancies comprising ~1% of all solid cancers in adults and including more than 70 histological and molecular subtypes with different pathological and clinical development characteristics. Over the last two decades, the increased knowledge of the...
Autores principales: | Caruso, Chiara, Garofalo, Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174622/ https://www.ncbi.nlm.nih.gov/pubmed/32351891 http://dx.doi.org/10.3389/fonc.2020.00509 |
Ejemplares similares
-
Targeted therapies for the treatment of soft tissue sarcoma
por: Fuchs, Jeffrey W., et al.
Publicado: (2023) -
Exosome-Based Liquid Biopsy Approaches in Bone and Soft Tissue Sarcomas: Review of the Literature, Prospectives, and Hopes for Clinical Application
por: Agnoletto, Chiara, et al.
Publicado: (2023) -
New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas
por: Seong, Gyuhee, et al.
Publicado: (2023) -
Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy
por: Du, Xin-Hui, et al.
Publicado: (2020) -
Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
por: Harrer, Dennis Christoph, et al.
Publicado: (2021)